United States - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry
Since 2014, United States Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry increased 4.5% year on year. With $70,565,318,932.39 Million PPP in 2019, the country was ranked number 1 among other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry. China, Japan and Germany respectively ranked number 2, 3 and 4 in this ranking. Iceland witnessed the best average annual growth at +43.9% per year, while Lithuania recorded the worst performance at -42.6% per year.
Loading...
| Date | Million US Dollars PPP |
|---|---|
| 2019 | 70,565,318,932.39 |
| 2018 | 68,324,504,216.39 |
| 2017 | 66,202,000,000.00 |
| 2016 | 64,628,000,000.00 |
| 2015 | 58,675,000,000.00 |
Download all data from 1987 to 2019
How does United States rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?
| # | 69 Countries | Million US Dollars PPP | Last | YoY | 5‑years CAGR | |
|---|---|---|---|---|---|---|
| 1 |
#1
United States
|
70,565,318,932.39 | 2019 | +3.3 % | +4.5 % | View data |
| 2 |
#2
China
|
13,956,388,273.35 | 2019 | +4.5 % | +6.1 % | View data |
| 3 |
#3
Japan
|
13,899,037,124.73 | 2019 | +3.5 % | -0.9 % | View data |
| 4 |
#4
Germany
|
6,508,976,256.92 | 2019 | +2.7 % | +4.4 % | View data |
| 5 |
#5
Switzerland
|
5,040,677,150.71 | 2019 | +3.2 % | +3.8 % | View data |